Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 17

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
Three months endedSeptember 30,Nine months endedSeptember 30,2025202420252024Revenue$205.7 $213.3 $614.7 $627.0 Cost of revenue61.9 63.5 184.9 192.5 Gross profit143.8 149.8 429.8 434.5 Costs and expenses:Research and development expense28.2 28.5 81.3 81.2 Sales and marketing expense71.0 69.9 212.1 212.1 General and administrative expense67.9 69.2 201.2 211.9 Goodwill and long-lived asset impairment charges— 2.2 316.7 13.8 Total operating expenses167.1 169.8 811.3 519.0 Operating loss(23.3)(20.0)(381.5)(84.5)Other income (expense):Interest income0.5 0.4 1.0 1.4 Interest expense(3.8)(0.8)(6.1)(2.1)Other0.4 (0.8)0.4 0.8 Total other income (expense), net(2.9)(1.2)(4.7)0.1 Loss before income tax(26.2)(21.2)(386.2)(84.4)Income tax expense (benefit)1.2 0.9 (28.2)0.4 Net loss$(27.4)$(22.1)$(358.0)$(84.8)Net loss per share:Basic and Diluted$(0.29)$(0.24)$(3.88)$(0.94)Weighted average shares outstanding:Basic and Diluted93.1 90.9 92.3 90.5 

See accompanying notes to Condensed Consolidated Financial Statements.

5

Table of Contents

 MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss (unaudited)

(in millions)

Three months endedSeptember 30,Nine months endedSeptember 30,2025202420252024Net loss$(27.4)$(22.1)$(358.0)$(84.8)Change in unrealized loss on available-for-sale debt